Edition:
United Kingdom

Alnylam Pharmaceuticals Inc (ALNY.OQ)

ALNY.OQ on NASDAQ Stock Exchange Global Select Market

87.88USD
25 Apr 2019
Change (% chg)

-- (--)
Prev Close
$87.88
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
289,771
52-wk High
$124.15
52-wk Low
$60.28

Latest Key Developments (Source: Significant Developments)

Regeneron Pharmaceuticals To Invest $800 Mln Through Upfront Cash And Equity Investment In Alnylam
Monday, 8 Apr 2019 

April 8 (Reuters) - Regeneron Pharmaceuticals Inc ::ALNYLAM AND REGENERON ANNOUNCE BROAD COLLABORATION TO DISCOVER, DEVELOP AND COMMERCIALIZE RNAI THERAPEUTICS FOCUSED ON OCULAR AND CENTRAL NERVOUS SYSTEM (CNS) DISEASES.REGENERON PHARMACEUTICALS INC - TO INVEST $800 MILLION THROUGH UPFRONT CASH AND EQUITY INVESTMENT IN ALNYLAM.REGENERON PHARMACEUTICALS - CO, ALNYLAM TO ALSO JOINTLY ADVANCE SELECT NUMBER OF PRECLINICAL DISEASE PROGRAMS WITH TARGETS EXPRESSED IN LIVER.REGENERON PHARMACEUTICALS - $400 MILLION UPFRONT PAYMENT TO ALNYLAM, BUY $400 MILLION OF ALNYLAM EQUITY AT $90.00/SHARE FOR 4.44 MILLION ALNYLAM COMMON SHARES.REGENERON PHARMACEUTICALS INC - ALNYLAM WILL WORK EXCLUSIVELY WITH REGENERON TO DISCOVER RNAI THERAPEUTICS FOR EYE AND CNS DISEASES.REGENERON PHARMACEUTICALS - ALNYLAM ELIGIBLE TO GET ADDITIONAL $200 MILLION IN MILESTONE PAYMENTS UPON ACHIEVEMENT OF CERTAIN CRITERIA.REGENERON - TO LEAD DEVELOPMENT, COMMERCIALIZATION FOR ALL PROGRAMS TARGETING EYE DISEASES, WITH ALNYLAM ENTITLED TO POTENTIAL MILESTONE, ROYALTY PAYMENTS.  Full Article

Silence Therapeutics Enters Settlement, License Deal With Alnylam
Monday, 10 Dec 2018 

Dec 10 (Reuters) - Silence Therapeutics PLC ::SETTLEMENT AND LICENSE AGREEMENT WITH ALNYLAM.ALNYLAM WILL LICENSE PATENTS FROM SILENCE & PAY A TIERED ROYALTY ON NET SALES OF ONPATTRO™ IN EU ONLY .ALNYLAM WILL PAY SILENCE A TIERED ROYALTY RANGING FROM 0.33 PERCENT TO 1.0 PERCENT THROUGH 2023 .  Full Article

Alnylam Says Safety Profile Of Givosiran "Encouraging" With Up To 25 Months Of Treatment
Friday, 9 Nov 2018 

Nov 9 (Reuters) - Alnylam Pharmaceuticals Inc ::ALNYLAM PRESENTS UPDATED PHASE 1/2 OPEN-LABEL EXTENSION (OLE) RESULTS FOR GIVOSIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC FOR THE TREATMENT OF ACUTE HEPATIC PORPHYRIA.ALNYLAM PHARMACEUTICALS INC - SAFETY PROFILE ENCOURAGING WITH UP TO 25 MONTHS OF TREATMENT.ALNYLAM PHARMACEUTICALS INC - GIVOSIRAN DEMONSTRATED SUSTAINED CLINICAL ACTIVITY.  Full Article

Silence Therapeutics Launches Interim European Injunction Application Against Onpattro
Friday, 12 Oct 2018 

Oct 12 (Reuters) - Silence Therapeutics PLC ::SILENCE THERAPEUTICS ANNOUNCES RECEIPT OF A NEW EUROPEAN NOTICE OF INTENTION TO GRANT A PATENT AND THE LAUNCH OF AN INTERIM EUROPEAN INJUNCTION APPLICATION AGAINST ONPATTRO™.SILENCE THERAPEUTICS - COMMENCED NEW CROSS-BORDER INTERIM INJUNCTION APPLICATION IN NETHERLANDS AGAINST ALNYLAM'S ONPATTRO.  Full Article

Silence Therapeutics Says U.S. PTAB Upholds Co's Patent
Thursday, 11 Oct 2018 

Oct 11 (Reuters) - Silence Therapeutics::SILENCE THERAPEUTICS PLC - REPORTS ON FAVOURABLE OUTCOME OF A DECISION BY US PTAB AGAINST ALNYLAM.SILENCE THERAPEUTICS - FAVOURABLE DECISION BY US PTAB RELATED TO POST GRANT REVIEW PETITIONS AGAINST CO'S NEWLY-ISSUED PATENTS FILED BY ALNYLAM.  Full Article

Alnylam Receives Positive CHMP Opinion For ONPATTRO(Patisiran)
Friday, 27 Jul 2018 

July 27 (Reuters) - Alnylam Pharmaceuticals Inc ::ALNYLAM RECEIVES POSITIVE CHMP OPINION FOR ONPATTRO™ (PATISIRAN) FOR THE TREATMENT OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS IN ADULTS WITH STAGE 1 OR STAGE 2 POLYNEUROPATHY.ALNYLAM PHARMACEUTICALS INC - EUROPEAN COMMISSION DECISION EXPECTED IN SEPTEMBER.ALNYLAM - IF APPROVED BY EUROPEAN COMMISSION, MEDICINE WILL BE COMMERCIALIZED UNDER BRAND NAME ONPATTRO.ALNYLAM PHARMACEUTICALS INC - REGULATORY FILINGS IN OTHER MARKETS, INCLUDING JAPAN, ARE PLANNED FOR MID-2018.  Full Article

Alnylam Pharma Co, Agilent Technologies Entered Manufacturing Services Agreement Providing For Supply Of Patisiran Drug Substance By Agilent
Tuesday, 3 Apr 2018 

April 4 (Reuters) - Alnylam Pharmaceuticals ::CO, AGILENT TECHNOLOGIES ENTERED MANUFACTURING SERVICES AGREEMENT PROVIDING FOR SUPPLY OF PATISIRAN DRUG SUBSTANCE BY AGILENT.AGREEMENT HAS INITIAL TERM OF 5 YEARS, WHICH IS SUBJECT TO AUTOMATIC RENEWAL TERMS OF 2 YEARS.PURSUANT TO AGREEMENT, CO REQUIRED TO PROVIDE ROLLING FORECASTS FOR PRODUCT ON QUARTERLY BASIS.‍PURSUANT TO DEAL, AGILENT HAS AGREED TO MANUFACTURE, SUPPLY TO CO, ACTIVE PHARMACEUTICAL INGREDIENTS REQUIRED FOR PATISIRAN FOR COMMERCIAL SALE​.WILL BE REQUIRED TO PROVIDE INITIAL PAYMENT TO COVER RAW MATERIAL PURCHASES AND RESERVE APPROPRIATE RESOURCES UNDER AGREEMENT.  Full Article

Regeneron, Alnylam Pharmaceuticals Announce Collaboration To Discover New Treatments For Nonalcoholic Steatohepatitis
Wednesday, 21 Mar 2018 

March 21 (Reuters) - Alnylam Pharmaceuticals Inc ::REGENERON AND ALNYLAM PHARMACEUTICALS ANNOUNCE COLLABORATION TO DISCOVER NEW TREATMENTS FOR NONALCOHOLIC STEATOHEPATITIS (NASH).ALNYLAM PHARMACEUTICALS INC - REGENERON WILL CONTRIBUTE RESEARCH ON HEPATOCYTE-EXPRESSED, GENETICALLY-VALIDATED HSD17B13 TARGET.ALNYLAM PHARMACEUTICALS INC - ALNYLAM WILL LEVERAGE ITS RNAI THERAPEUTICS PLATFORM TO IDENTIFY COMPOUNDS DIRECTED TO TARGET.ALNYLAM - CO, REGENERON INTEND TO ENTER SEPARATE, 50-50 COLLABORATION TO FURTHER RESEARCH, CO-DEVELOP ANY THERAPEUTIC PRODUCT COMING FROM DISCOVERY.  Full Article

Alnylam Retains Global Rights To Lumasiran, Investigational RNAi Therapeutic For Treatment Of Primary Hyperoxaluria Type 1
Monday, 12 Mar 2018 

March 12 (Reuters) - Alnylam Pharmaceuticals Inc ::ALNYLAM RETAINS GLOBAL RIGHTS TO LUMASIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC FOR THE TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 (PH1).ALNYLAM PHARMACEUTICALS INC - ‍COMPANY PLANS TO ACCELERATE DEVELOPMENT WITH PHASE 3 START IN LATE 2018​.ALNYLAM PHARMACEUTICALS INC - ‍LUMASIRAN GRANTED BREAKTHROUGH THERAPY DESIGNATION BY UNITED STATES FOOD AND DRUG ADMINISTRATION​.ALNYLAM PHARMACEUTICALS INC - ‍SANOFI GENZYME HAS DECLINED ITS OPT-IN FOR DEVELOPMENT AND COMMERCIALIZATION OF LUMASIRAN​.  Full Article

Alnylam Pharmaceuticals Q4 Non-Gaap Loss Per Share $1.20
Thursday, 8 Feb 2018 

Feb 8 (Reuters) - Alnylam Pharmaceuticals Inc ::ALNYLAM PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PERIOD ACTIVITY.Q4 NON-GAAP LOSS PER SHARE $1.20.EXPECTS TO END 2018 WITH APPROXIMATELY $1.0 BILLION IN CASH.REAFFIRMED GUIDANCE TO INITIATE A COMPREHENSIVE PHASE 3 PROGRAM FOR ALN-TTRSC02 IN LATE 2018.QTRLY LOSS PER SHARE $1.48.REVENUES WERE $37.9 MILLION IN Q4 OF 2017, AS COMPARED TO $17.5 MILLION IN Q4 OF 2016.Q4 EARNINGS PER SHARE VIEW $-1.39 -- THOMSON REUTERS I/B/E/S.EXPECTS 2018 ANNUAL NON-GAAP RESEARCH AND DEVELOPMENT EXPENSES TO BE IN RANGE OF $400 MILLION TO $440 MILLION.Q4 REVENUE VIEW $21.8 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

UPDATE 2-Regeneron forays into gene-silencing therapies with Alnylam tie-up

April 8 Regeneron Pharmaceuticals Inc said it would invest $800 million in Alnylam Pharmaceuticals Inc to develop treatments for eye and central nervous system diseases using gene-silencing RNA interference (RNAi) technology.